Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$14.40 +1.8%	$13.88	$10.83 ▼ $63.00	$281.52M	1.51	45,802 shs	49,639 shs
CDXS Codexis	$2.73 +0.4%	$2.80	$1.90 ▼ $6.08	$246.43M	2.54	915,649 shs	513,973 shs
SNSS Sunesis Pharmaceuticals		$3.53	$1.12 ▼ $11.30	$96.26M	2.27	4.33 million shs	1.20 million shs
VNDA Vanda Pharmaceuticals	$4.73 +0.6%	$4.62	$3.81 ▼ $5.55	$279.50M	0.72	562,356 shs	277,953 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	-0.70%	-1.74%	+15.04%	-98.16%	-98.16%
CDXS Codexis	+1.87%	-3.55%	-3.55%	+17.75%	-6.53%
SNSS Sunesis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VNDA Vanda Pharmaceuticals	+1.73%	+4.21%	+0.43%	+7.06%	-10.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Crescent Biopharma	3.7571 of 5 stars	4.7	0.0	0.0	3.7	2.5	1.7	0.6
CDXS Codexis	3.808 of 5 stars	3.3	2.0	0.0	2.5	3.6	1.7	0.6
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	4.4554 of 5 stars	3.8	2.0	0.0	4.2	2.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	3.33	Buy	$25.60	77.78% Upside
CDXS Codexis	2.50	Moderate Buy	$11.00	302.93% Upside
SNSS Sunesis Pharmaceuticals	0.00	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	248.84% Upside

Current Analyst Ratings Breakdown

Latest SNSS, CBIO, VNDA, and CDXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/25/2025	CBIO Crescent Biopharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
8/21/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	$6.92 per share	N/A
CDXS Codexis	$57.16M	4.31	N/A	N/A	$0.62 per share	4.40
SNSS Sunesis Pharmaceuticals	$2.07M	0.00	N/A	N/A	$1.42 per share	0.00
VNDA Vanda Pharmaceuticals	$198.77M	1.41	N/A	N/A	$8.23 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
CDXS Codexis	-$65.28M	-$0.83	N/A	N/A	N/A	-113.67%	-105.83%	-46.06%	10/30/2025 (Estimated)
SNSS Sunesis Pharmaceuticals	-$23.33M	-$2.70	N/A	N/A	N/A	N/A	-179.05%	-72.27%	N/A
VNDA Vanda Pharmaceuticals	-$18.90M	-$1.13	N/A	N/A	N/A	-32.90%	-12.89%	-10.47%	11/5/2025 (Estimated)

Latest SNSS, CBIO, VNDA, and CDXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	CDXS Codexis	-$0.17	-$0.16	+$0.01	-$0.16	$14.18 million	$15.33 million
7/31/2025	Q2 2025	VNDA Vanda Pharmaceuticals	-$0.34	-$0.46	-$0.12	-$0.46	$54.77 million	$52.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CDXS Codexis	N/A	N/A	N/A	N/A	N/A
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	9.21	9.21
CDXS Codexis	0.71	5.82	5.70
SNSS Sunesis Pharmaceuticals	N/A	7.74	7.74
VNDA Vanda Pharmaceuticals	N/A	3.25	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
CDXS Codexis	78.54%
SNSS Sunesis Pharmaceuticals	28.41%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	4.00%
CDXS Codexis	1.90%
SNSS Sunesis Pharmaceuticals	4.22%
VNDA Vanda Pharmaceuticals	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
CDXS Codexis	250	90.27 million	88.55 million	Optionable
SNSS Sunesis Pharmaceuticals	24	18.09 million	N/A	Optionable
VNDA Vanda Pharmaceuticals	290	59.09 million	53.18 million	Optionable

SNSS, CBIO, VNDA, and CDXS Headlines

Recent News About These Companies

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

2 hours ago | seekingalpha.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...

August 29 at 4:27 AM | finanznachrichten.de

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

August 28 at 5:23 PM | prnewswire.com

Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B

August 28 at 10:10 AM | seekingalpha.com

Vanda Pharmaceuticals stock rises after FDA orphan drug designation

August 28 at 8:23 AM | za.investing.com

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

August 28 at 7:00 AM | prnewswire.com

Vanda Pharmaceuticals treatment of polycythemia vera granted orphan designation

August 27 at 2:11 AM | msn.com

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at HC Wainwright

August 23, 2025 | marketbeat.com

Vanda seeks FDA Commissioner review of Hetlioz generic ruling

August 22, 2025 | msn.com

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

August 21, 2025 | prnewswire.com

Vanda wins appeals court fight over FDA jet lag ruling

August 19, 2025 | thepharmaletter.comT

Vanda Pharmaceuticals Shares Climb After Court Reverses FDA Decision

August 18, 2025 | msn.com

Vanda Pharmaceuticals shares rise after court overturns FDA denial

August 18, 2025 | za.investing.com

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark

August 18, 2025 | msn.com

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

August 18, 2025 | prnewswire.com

HC Wainwright Issues Pessimistic Outlook for VNDA Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Has Bearish Forecast for VNDA Q4 Earnings

August 15, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $4.27 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

August 15, 2025 | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Misses Expectations By $0.12 EPS

August 3, 2025 | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by Wall Street Zen to Strong Sell

August 3, 2025 | marketbeat.com

Short Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Increases By 2,603.2%

August 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSS, CBIO, VNDA, and CDXS Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$14.40 +0.25 (+1.77%)

As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Codexis NASDAQ:CDXS

$2.73 +0.01 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 -0.03 (-1.10%)

As of 05:36 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.73 +0.03 (+0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$4.59 -0.14 (-3.04%)

As of 05:02 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time